Stock News
Revolutionizing Ebola Treatment: RedHill Biopharma Receives Government Funding to Advance Opaganib
Innovative Drug Opaganib Selected for Joint Development and Funding to Treat Ebola Virus Disease BARDA Partners with Opaganib for Advancing Treatment for EBOV The U.S. government’s Biomedical Advanced Research and Development Authority (BARDA) recently announced their selection of opaganib for joint development and funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)….
Get Ready to LOL: The Inside Scoop on the Latest Article You Can’t Miss!
Hold on to Your Wallets: Sunlight Financial Faces Class Action Lawsuit Cheer up, Sunlight Financial Holdings, Inc. – You’re Going to Court! What’s Going On? Oh boy, here we go! Buckle up, folks, because Sunlight Financial Holdings, Inc. (or should we say Spartan Acquisition Corp. II?) is in hot water. A class action lawsuit has…
Q32 Bio to Present Positive Phase 1 Results of Tissue-Targeted Complement Inhibitor ADX-097 at American Society of Nephrology Kidney Week 2024
Exciting News from Q32 Bio Inc. at ASN Kidney Week 2024 Poster Presentation Highlights Data from ADX-097 Clinical Trial At the upcoming American Society of Nephrology (ASN) Kidney Week 2024, Q32 Bio Inc. will be presenting data from a completed Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers. The results of this…
Get Ready to Laugh and Relate: Lilly’s Study Shows Mirikizumab is a Game-Changer for Crohn’s Disease!
Exciting News for Crohn’s Disease Patients! Breaking New Ground in Treatment Hey there fellow Crohn’s disease warriors, have you heard the latest groundbreaking news? New data from Eli Lilly and Company has shown that more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab, regardless of prior biologic experience. This is…
Big Pharma Gets a Brain Boost: Lundbeck Snags Longboard in Epic Acquisition!
Welcome to the Lundbeck & Longboard Story! By: Your Friendly Neighborhood Blogger Hey there, fellow enthusiasts of all things interesting and nerd worthy, I have a bombshell of a story for you today! Lundbeck and Longboard are shaking up the pharmaceutical world with their recent agreement that has tongues wagging and minds buzzing. In case…
Act Now: Investor Deadline Approaching – Robbins Geller Rudman & Dowd LLP Launches Class Action Lawsuit Against Extreme Networks Inc. for Investors with Significant Losses
Act Now: Investor Deadline Approaching – Robbins Geller Rudman & Dowd LLP Launches Class Action Lawsuit Against Extreme Networks Inc. Description: SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of Extreme Networks, Inc. (NASDAQ: EXTR) common stock between July 27, 2022, and January 30, 2024, all…
Redwire Set to Deliver Major European Satellite in Fourth Quarter, Meeting Growing International Demand
Redwire Corporation Prepares for Satellite Delivery Overview Redwire Corporation, a leading provider of space infrastructure solutions, has announced its plans to finalize the integration and delivery of two satellites for the European Space Agency’s Proba-3 mission. This mission is set to take place in the fourth quarter of this year, marking a significant milestone in…
Breaking News: Ardena Takes Big Step in US Expansion with Acquisition of Cutting-Edge Drug Manufacturing Facility from Catalent
Breaking News: Ardena Takes Big Step in US Expansion with Acquisition of Cutting-Edge Drug Manufacturing Facility from Catalent Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) Ardena Expanding its Reach Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, has made a groundbreaking move in…